BAAR, Switzerland, May 31, 2025--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented ...

The first phase of Honkai Star Rail 3.3 is nearing its end, and Trailblazers are eagerly waiting for the upcoming 5-star unit, Cipher. Your login session has expired.

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab reduced the risk of progression or death by 48% in patients with ...

The Phase 3 study successfully met its primary endpoint, demonstrating the non-inferiority of tebipenem HBr to the intravenous antibiotic imipenem-cilastatin in treating hospitalized adult ...

The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout. The trial of 1,690 hospitalized patients with ...

NiOh 3 is due out in early 2026 on PlayStation 4, and an alpha demo is currently available on the PlayStation 5 via the PS Store. The big change with NiOh 3 is the addition of new ninja-based ...

WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company, today announced successful outcomes from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction ...

We report the interim analysis of efficacy and safety outcomes of Padeliporfin VTP for treatment of LG UTUC in ENLIGHTED, a Phase 3 trial (NCT04620239). Methods: This is an open-label phase 3 study ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...